Nasdaq-listed Moderna will start to transfer the know-how to Lonza in June this year, and the two parties are targeting the first batches of the mRNA-1273 to be made the following month.
SINGAPORE (May 1): Swiss pharmaceutical company Lonza Group, which has a secondary listing on SGX, has announced a ten-year deal with US-based Moderna to undertake large scale manufacturing of the latter’s mRNA-1273, which is a vaccine that is being tested for use against the novel coronavirus.
Under the terms of the agreement, the two parties plan to establish manufacturing suites at Lonza’s facilities in the US and Switzerland for the manufacture of mRNA-1273.
